Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib—Report of Three Cases

Pazopanib is a potent multi-kinase inhibitor that hinders angiogenesis and blocks tumor growth. It has been approved for the treatment of metastatic renal cell carcinoma (mRCC) and advanced soft tissue sarcoma. There is emerging evidence that bleeding is a common adverse effect of pazopanib and othe...

Description complète

Détails bibliographiques

Auteurs principaux:	Erofili Papadopoulou, Emmanouil Vardas, Styliani Tziveleka, Maria Georgaki, Maria Kouri, Konstantinos Katoumas, Evangelia Piperi, Nikolaos G. Nikitakis
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2022-12-01
Collection:	Dentistry Journal
Sujets:	pazopanib angiogenesis inhibitors gingival bleeding jaw osteonecrosis oral side effects metastatic renal cell carcinoma
Accès en ligne:	https://www.mdpi.com/2304-6767/10/12/232
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!